Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
GLTO
Galecto Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for GLTO
Full GLTO profile on Quantisnow Follow GLTO and get a push notification the moment its next story breaks.